About Mesoblast
Mesoblast is a company based in Melbourne (Australia) founded in 2004. The company has 81 employees as of June 30, 2025. Mesoblast has completed 2 acquisitions, including Angioblast Systems and Provasculon. Mesoblast operates in a competitive market with competitors including RoosterBio, SanBio, Cellular Biomedicine Group, BrainStorm Cell and SCM Lifescience, among others.
- Headquarter Melbourne, Australia
- Employees 81 as on 30 Jun, 2025
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mesoblast Limited
-
Annual Revenue
$17.34 M (USD)194.84as on Jun 30, 2025
-
Net Profit
-$102.99 M (USD)-17.5as on Jun 30, 2025
-
EBITDA
-$56.6 M (USD)-4.85as on Jun 30, 2025
-
Latest Funding Round
$159.98 M (USD), Post-IPO
Jan 14, 2025
-
Investors
Hercules Capital
& 5 more
-
Employee Count
81
as on Jun 30, 2025
-
Investments & Acquisitions
Angioblast Systems
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mesoblast
Mesoblast is a publicly listed company on the ASX with ticker symbol MSB in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Mesoblast
Unlock access to complete
Software Development Team
9 people
Leadership Team
7 people
Finance and Accounting
5 people
Operations Team
4 people
Product Management Team
4 people
Principal Team
2 people
Senior Team
2 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Mesoblast
Investors in Mesoblast
Mesoblast has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, M&G and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified asset management firm and private fund focused on debt and equity investments in climate startups, real estate, and multiple sectors
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Provider of public, living relief, strengthening medicare, jobs, skills and training services
|
Locked | Locked | Locked |
Investor details for Mesoblast
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mesoblast
Mesoblast has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Angioblast Systems and Provasculon.
Investment portfolio details for Mesoblast
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
New blood vessel growth is stimulated through SDF-1 regenerative solutions.
|
Locked | Locked | 2007 | Locked | |
|
Therapeutic products for cardiovascular diseases are developed and commercialized.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Mesoblast
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Mesoblast
Detailed financials for Mesoblast
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mesoblast Comparisons
Peer comparison for Mesoblast
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mesoblast
Mesoblast operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RoosterBio, SanBio, Cellular Biomedicine Group, BrainStorm Cell and SCM Lifescience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| Locked | Locked | Locked |
Regenerative cell medicines for neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Cellular therapeutics are developed for cancer, orthopaedics, and COPD.
|
|
| Locked | Locked | Locked |
Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD
|
|
| Locked | Locked | Locked |
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
|
Detailed competitors of Mesoblast
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mesoblast
Complete news archive for Mesoblast
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mesoblast
Mesoblast was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Mesoblast is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
As of Jun 30, 2025, the latest employee count at Mesoblast is 81.
Annual revenue of Mesoblast is $17.34M as on Jun 30, 2025.
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low back pain due to degenerative disc disease.
Mesoblast's top competitors include RoosterBio, SanBio and BrainStorm Cell.
Yes, Mesoblast is publicly traded on ASX under the ticker symbol MSB.
Mesoblast has made 2 acquisitions, including Angioblast Systems, and Provasculon.
Mesoblast has 6 investors. Key investors include Hercules Capital, M&G, Celgene, Cephalon, and Government of Australia.
The ticker symbol of Mesoblast is MSB on ASX.